Expert Opinion on Therapeutic Patents

Papers
(The TQCC of Expert Opinion on Therapeutic Patents is 15. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)
ArticleCitations
Multicomponent reactions (MCR) in medicinal chemistry: a patent review (2010-2020)116
SARS-CoV-2 RNA-dependent RNA polymerase as a therapeutic target for COVID-1983
Antibacterial carbonic anhydrase inhibitors: an update on the recent literature54
An updated patent review of p38 MAP kinase inhibitors (2014-2019)51
SARS, MERS and SARS-CoV-2 (COVID-19) treatment: a patent review46
Repurposing drugs for the management of COVID-1944
Antimicrobial peptides (AMPs): a patent review (2015–2020)43
Small molecule DNA-PK inhibitors as potential cancer therapy: a patent review (2010–present)37
Sirtuin modulators: where are we now? A review of patents from 2015 to 201937
Biofilm and Quorum Sensing inhibitors: the road so far36
Xanthine oxidase inhibitors: patent landscape and clinical development (2015–2020)35
N-Methyl-D-Aspartate (NMDA) receptor modulators: a patent review (2015-present)33
Natural compounds and extracts as novel antimicrobial agents32
Antibiotic resistance and bacterial biofilm32
Inhibitory activities of indolizine derivatives: a patent review32
Microneedles as an alternative technology for transdermal drug delivery systems: a patent review31
Small-molecule CSF1R kinase inhibitors; review of patents 2015-present31
Coronavirus helicases: attractive and unique targets of antiviral drug-development and therapeutic patents31
Acetylcholinesterase inhibitors for the treatment of Alzheimer’s disease – a patent review (2016–present)30
The therapeutic potential of PROTACs29
An updated patent review of VEGFR-2 inhibitors (2017-present)28
A deadly spillover: SARS-CoV-2 outbreak28
Phosphatidylinositol 3-kinase (PI3K) inhibitors: a recent update on inhibitor design and clinical trials (2016–2020)28
An updated patent review of anticancer Hsp90 inhibitors (2013-present)27
An updated patent review of galectin-1 and galectin-3 inhibitors and their potential therapeutic applications (2016–present)27
Synthetic molecules as DprE1 inhibitors: A patent review27
Neurokinin receptor antagonism: a patent review (2014-present)26
Transient receptor potential ankyrin 1 (TRPA1) antagonists: a patent review (2015–2019)26
Targeting PRC2 for the treatment of cancer: an updated patent review (2016 - 2020)26
Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2016–2019)23
Soluble guanylate cyclase stimulators and their potential use: a patent review22
Current trends of benzothiazoles in drug discovery: a patent review (2015–2020)22
Small-molecule BACE1 inhibitors: a patent literature review (2011 to 2020)22
Protease inhibitors targeting the main protease and papain-like protease of coronaviruses22
Marine natural products as source of new drugs: an updated patent review (July 2018-July 2021)22
Small-molecule CD73 inhibitors for the immunotherapy of cancer: a patent and literature review (2017–present)21
TRPV4 antagonists: a patent review (2015–2020)20
Hypoxia-inducible factor (HIF) inhibitors: a patent survey (2016–2020)20
O-GlcNAcase inhibitors as potential therapeutics for the treatment of Alzheimer’s disease and related tauopathies: analysis of the patent literature20
Ligands for cereblon: 2017–2021 patent overview20
Factor XII(a) inhibitors: a review of the patent literature19
Small molecule agonists of toll-like receptors 7 and 8: a patent review 2014 – 202019
A patent review of myeloperoxidase inhibitors for treating chronic inflammatory syndromes (focus on cardiovascular diseases, 2013-2019)19
A 2018–2019 patent review of metallo beta-lactamase inhibitors19
A patent review of topoisomerase I inhibitors (2016–present)19
Antiviral therapeutics for chikungunya virus19
Novel ligands and modulators of triggering receptor expressed on myeloid cells receptor family: 2015-2020 updates19
Steroid sulfatase inhibitors: the current landscape19
ATP-citrate lyase (ACLY) inhibitors as therapeutic agents: a patenting perspective18
Novel matrix metalloproteinase inhibitors: an updated patent review (2014 - 2020)18
Anticancer carbonic anhydrase inhibitors: a patent and literature update 2018-202218
An updated patent review of monoacylglycerol lipase (MAGL) inhibitors (2018-present)18
Thioredoxin reductase inhibitors: updated patent review (2017-present)18
Inhibitors of type II transmembrane serine proteases in the treatment of diseases of the respiratory tract – A review of patent literature17
An updated patent review of autotaxin inhibitors (2017–present)17
Progress with YAP/TAZ-TEAD inhibitors: a patent review (2018-present)17
GPR120 agonists for the treatment of diabetes: a patent review (2014 present)17
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: a patent review (2014-present)16
A patent review of transient receptor potential vanilloid type 1 modulators (2014–present)16
Small molecule glucagon receptor antagonists: an updated patent review (2015–2019)16
An updated patent review on drugs for the treatment of tuberculosis (2018-present)15
Recent updates on Wnt signaling modulators: a patent review (2014-2020)15
Recent development in the discovery of PARP inhibitors as anticancer agents: a patent update (2016-2020)15
Therapeutic approaches targeting the neurotensin receptors15
A patent review of adaptor associated kinase 1 (AAK1) inhibitors (2013-present)15
Anti-viral activity of thiazole derivatives: an updated patent review15
Soluble epoxide hydrolase inhibitors: an overview and patent review from the last decade15
0.027852058410645